Belsomra vs Trazodone Head-to-Head Efficacy: What the Evidence Actually Shows

Why There Is No Direct Head-to-Head Trial

Clinicians searching for a clean "Belsomra beats trazodone" or vice versa verdict will not find one. No published randomized controlled trial has enrolled patients to compare the two drugs directly. Both agents treat insomnia, but they entered the literature through entirely separate regulatory and research pathways, which means any comparison must be built from parallel trial evidence rather than a single study.

How Each Drug Reached Insomnia Practice

Suvorexant was designed specifically for insomnia. Merck submitted two key Phase 3 trials to the FDA before the drug received approval in August 2014 [1]. Trazodone, by contrast, earned FDA approval in 1981 as an antidepressant [2]. Sleep practitioners adopted it for insomnia based on its sedating side-effect profile, not on insomnia-specific approval.

What This Means for Interpreting the Evidence

Because the two drugs were never tested against each other, every comparative statement in this article is an indirect inference. The populations in each trial differed, the outcome definitions differed, and the follow-up durations differed. Physicians at HealthRX weight indirect comparisons cautiously.

Suvorexant: Mechanism and FDA Trial Data

Suvorexant blocks orexin A and orexin B from binding OX1R and OX2R receptors [3]. Orexin peptides are produced in the lateral hypothalamus and actively sustain wakefulness. By blocking those signals, suvorexant allows sleep to emerge rather than chemically inducing sedation. This mechanism is distinct from benzodiazepines and Z-drugs, which act on GABA-A receptors and carry higher dependency and complex-sleep-behavior risk [4].

The Herring et al. Lancet Neurology 2014 Trial

The most cited suvorexant efficacy study is Herring et al. (Lancet Neurology, 2014), a Phase 3 randomized, double-blind, placebo-controlled trial in 1,021 adults with primary insomnia [5]. Participants received either 15 mg and 40 mg (age <65) or 10 mg and 30 mg (age 65+) suvorexant or placebo nightly for 3 months, with a 3-month follow-up.

Key outcomes at 1 month:

• Subjective time to sleep onset (sTSO) was reduced by approximately 22 minutes vs. Placebo.
• Subjective wake after sleep onset (sWASO) fell by roughly 28 minutes vs. Placebo.
• Polysomnographic (PSG) wake after sleep onset decreased significantly at both dose levels (P<0.001 vs. Placebo for the higher dose group).

The study also provided long-term data: benefits were maintained at 3 months with no clinically significant rebound insomnia upon discontinuation [5].

The Phase 3 Trial 1 (Michelson et al. 2014) Outcomes

A companion Phase 3 trial published in the same year (Michelson et al., Sleep Medicine, N=1,022) confirmed consistent findings across a non-Japanese adult population [6]. Subjective TSO improved by 15 to 20 minutes over placebo, and subjective WASO improved by 20 to 28 minutes. Safety was broadly similar to placebo, though next-morning somnolence occurred in roughly 7% of patients on higher doses [6].

FDA-Approved Doses and the Dose-Reduction Decision

The FDA approved suvorexant at 10 mg (starting dose) with a maximum of 20 mg nightly [1]. The Phase 3 trials tested 40 mg and 80 mg doses but the FDA requested approval at lower doses because the benefit-risk ratio at 10 to 20 mg was favorable and higher doses carried more residual impairment [4]. Prescribers should follow current labeling, not trial doses.

Trazodone: Mechanism and the Off-Label Evidence Base

Trazodone's sedation arises primarily from antagonism at histamine H1 receptors and serotonin 5-HT2A receptors [7]. At low doses (25 to 150 mg), the antihistaminergic and antiserotonergic effects dominate over its serotonin reuptake inhibition, which requires higher doses (150 to 400 mg) for antidepressant effect. That pharmacological split is precisely why clinicians dose it differently for sleep than for depression [8].

The Mendelson 2005 RCT

Mendelson (Journal of Clinical Psychiatry, 2005) conducted a randomized, double-blind, placebo-controlled polysomnographic study in 306 adults with primary insomnia [9]. Participants received trazodone 50 mg or placebo for two weeks. Trazodone reduced PSG-measured wake after sleep onset by a mean of 7.8 minutes vs. Placebo, a statistically significant but modest effect. Subjective sleep quality scores improved more robustly (P<0.05) [9]. Critically, the trial lasted only two weeks, so there is no comparator long-term dataset matching the 3-month Herring suvorexant data.

A 2017 Systematic Review and the Evidence Gap

A 2017 systematic review by Everitt et al. In PLOS One analyzed trazodone's use as a hypnotic and found that while the drug improved subjective sleep quality, most trials had short durations and small sample sizes [10]. The authors concluded that "the evidence base for trazodone as a hypnotic is considerably weaker than for approved hypnotics," noting that publication bias may inflate the observed effect sizes [10].

Why Trazodone Remains So Widely Prescribed

Trazodone is not a Schedule IV controlled substance, unlike suvorexant, zolpidem, and eszopiclone [8]. For patients with a history of substance use disorder, or for clinicians who want to avoid DEA scheduling paperwork, that distinction matters practically. A 2017 analysis using IMS Health data estimated that trazodone accounted for approximately 15 to 20% of all hypnotic prescriptions in the United States, despite its off-label status for insomnia [11].

Indirect Efficacy Comparison: Sleep Onset vs. Sleep Maintenance

When comparing outcomes across separate trials, two questions matter most: which drug works for sleep onset, and which works for sleep maintenance.

Sleep Onset (Latency)

Suvorexant reduced subjective sleep onset latency by 15 to 22 minutes vs. Placebo across both Phase 3 trials [5, 6]. Trazodone data on sleep latency are inconsistent. In the Mendelson 2005 trial, no statistically significant effect on PSG-measured sleep latency was reported [9]. A smaller crossover trial by Kaynak et al. (Sleep Medicine, 2004, N=16) found trazodone 100 mg reduced sleep latency in patients with major depression, but that population had elevated baseline latency from depression itself, limiting generalizability [12].

For pure insomnia with prominent sleep-onset complaints, suvorexant has the stronger published evidence.

Sleep Maintenance (Wake After Sleep Onset)

Suvorexant's WASO reduction was 20 to 28 minutes vs. Placebo at 1 month in Herring et al. [5]. Trazodone's WASO reduction was approximately 7.8 minutes vs. Placebo in Mendelson 2005 [9]. On this metric, suvorexant shows a numerically larger effect in the available trials, though a direct statistical comparison is not possible.

Total Sleep Time

Herring et al. Reported a mean PSG total sleep time (TST) increase of approximately 23 minutes vs. Placebo [5]. Mendelson 2005 reported a TST increase of approximately 19 minutes vs. Placebo for trazodone 50 mg [9]. These numbers are superficially close, but the methodological differences between the trials prevent a confident conclusion.

Safety and Tolerability: Where the Drugs Diverge

Both drugs carry next-morning impairment risk, but via different mechanisms and at different magnitudes.

Suvorexant Safety Profile

The FDA drug label for suvorexant lists somnolence (7% at 20 mg vs. 3% placebo), sleep paralysis, hypnagogic or hypnopompic hallucinations, and cataplexy-like symptoms at higher doses as notable adverse events [4]. Complex sleep behaviors (sleep-driving, sleep-eating) have been reported, though less frequently than with Z-drugs [4]. The FDA added a Boxed Warning in 2019 for all sleep medicines regarding complex sleep behaviors [2].

Trazodone Safety Profile

Trazodone's tolerability concerns differ substantially. Orthostatic hypotension affects roughly 5% of patients in clinical practice [8]. Priapism is rare (estimated 1 in 6,000 to 1 in 10,000 male patients) but is a medical emergency [13]. Next-morning grogginess is common at doses above 100 mg. Trazodone also carries a class-level antidepressant black-box warning for suicidal ideation in patients under age 25, which applies even when the drug is used solely for sleep [8].

Dependency and Withdrawal Risk

Suvorexant is Schedule IV, implying recognized abuse potential, yet clinical trials show no significant physiological withdrawal or rebound insomnia at approved doses [5]. Trazodone is not scheduled and does not produce classic hypnotic physical dependence, though abrupt discontinuation after prolonged use can trigger insomnia rebound [9].

Special Populations: Who Does Better on Which Drug

The following decision framework reflects standard clinical reasoning used by the HealthRX medical team when selecting between suvorexant and trazodone for insomnia.

Patients with Comorbid Depression or Anxiety

Trazodone may serve double duty in patients with mild-to-moderate depression who need both a hypnotic and a low-level antidepressant effect at night. The FDA-approved antidepressant dose is 150 to 400 mg, which is higher than the 50 to 100 mg typically used for sleep, so calling this a dual-indication strategy requires careful dosing expectations [8]. The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for chronic insomnia suggests a "weak recommendation" for trazodone in patients with comorbid depression [14].

Older Adults

The AASM 2017 guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults (GRADE: weak recommendation, low quality evidence)" [14]. For adults 65 and older, suvorexant's approved maximum dose is 20 mg, and the Phase 3 data include a specific elderly sub-cohort with acceptable safety [5]. The 2023 Beers Criteria from the American Geriatrics Society flags sedating antidepressants including trazodone as potentially inappropriate in older adults because of fall and fracture risk [15].

Patients with Substance Use Disorder History

Trazodone's unscheduled status and absence of GABA-related dependence mechanisms make it a common choice when the prescriber wants to avoid controlled substances. Suvorexant, though Schedule IV, has a mechanism that does not directly interact with the addiction circuitry the way opioids or benzodiazepines do [3].

Patients with Predominant Sleep-Onset Insomnia

Suvorexant's documented effect on subjective and PSG-measured sleep latency in two large Phase 3 trials gives it a more evidence-supported claim for this complaint [5, 6].

Dosing Protocols Side by Side

Both drugs require low starting doses and patient-specific titration.

| Parameter | Suvorexant (Belsomra) | Trazodone (off-label) | |---|---|---| | Starting dose | 10 mg nightly | 25 to 50 mg nightly | | Typical maintenance dose | 10 to 20 mg nightly | 50 to 100 mg nightly | | Maximum approved/used dose | 20 mg (FDA label) | 150 mg (insomnia); 400 mg (depression) | | Timing | 30 min before bed | 30 to 60 min before bed | | DEA schedule | Schedule IV | Unscheduled | | Renal adjustment | Not required | Not required | | Hepatic adjustment | Use caution with severe impairment | Use caution with severe impairment |

For suvorexant, the FDA label specifies that the drug should not be taken unless the patient can devote a full 7 hours to sleep [4]. For trazodone, orthostatic hypotension risk is higher in the first 1 to 2 hours after ingestion, so patients should be counseled to avoid standing rapidly during this window [8].

Cost and Access

Suvorexant remains branded (Belsomra) through 2030 when its primary patent exclusivity window closes; generic suvorexant is not yet widely available as of early 2025 [1]. A 30-day supply of 10 mg Belsomra lists at roughly $370, $420 without insurance, though manufacturer savings cards can reduce out-of-pocket cost to as low as $15 for eligible commercially insured patients [4].

Trazodone is generic and costs approximately $10, $25 for a 30-day supply at standard pharmacies [8]. This price difference is clinically relevant for uninsured patients and those on high-deductible plans.

Guideline Positioning

The AASM 2017 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults provides the most relevant positioning for both agents [14]. The guideline rates suvorexant with a weak recommendation based on moderate-quality evidence for sleep onset and maintenance. Trazodone receives a weak recommendation based on low-quality evidence, specifically for patients with comorbid depression. Neither drug receives a strong recommendation, which reflects the AASM's overall preference for cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment [14].

The guideline notes: "The Task Force suggests that clinicians use suvorexant as a treatment for sleep onset insomnia... And sleep maintenance insomnia... In adults with chronic insomnia disorder (versus no treatment)" [14].

A 2022 Cochrane review of pharmacological interventions for insomnia disorder found that while benzodiazepine receptor agonists had more evidence, orexin antagonists showed a growing evidence base with fewer safety signals than older hypnotics [16].

Switching Between Suvorexant and Trazodone

Patients may be switched for reasons including inadequate efficacy, side effects, cost, or changes in comorbidities. No published protocol exists specifically for this drug pair. General principles from sleep pharmacology practice apply:

1. Taper the current agent rather than stopping abruptly, particularly if the patient has been on trazodone for more than 4 weeks (rebound insomnia risk).
2. Introduce the new agent at its lowest dose on the first night after the final dose of the prior drug, or after a 24-hour washout if transitioning to suvorexant.
3. Expect 1 to 2 weeks of adjustment before assessing the new agent's efficacy.
4. Monitor for orthostatic symptoms if moving to trazodone, and for next-morning impairment if moving to suvorexant [8, 4].

The FDA label for suvorexant does not specify a washout period when switching from other hypnotics [4]. Clinicians should exercise individual judgment based on the patient's renal and hepatic function, age, and concurrent medications.